🇺🇸 Umbilical cord blood in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 13

Most-reported reactions

1. Stem Cell Transplant — 2 reports (15.38%)
2. Transplant Failure — 2 reports (15.38%)
3. Vomiting — 2 reports (15.38%)
4. Acute Myeloid Leukaemia — 1 report (7.69%)
5. Acute Respiratory Failure — 1 report (7.69%)
6. Asthenia — 1 report (7.69%)
7. Bacteraemia — 1 report (7.69%)
8. Blood Calcium Increased — 1 report (7.69%)
9. Blood Iron Decreased — 1 report (7.69%)
10. Burning Sensation — 1 report (7.69%)

Source database →

Frequently asked questions

Is Umbilical cord blood approved in United States?

Umbilical cord blood does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Umbilical cord blood in United States?

Shandong Qilu Stem Cells Engineering Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.